These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 37242206)

  • 1. Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease.
    Bhat N; Mani A
    Nutrients; 2023 May; 15(10):. PubMed ID: 37242206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling.
    Sunami Y
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes.
    Fernandes GW; Bocco BMLC
    Curr Diabetes Rev; 2021; 17(7):e110320187539. PubMed ID: 33143628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.
    Engin A
    Adv Exp Med Biol; 2024; 1460():539-574. PubMed ID: 39287864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD.
    Vacca M; Allison M; Griffin JL; Vidal-Puig A
    Semin Liver Dis; 2015 Aug; 35(3):250-61. PubMed ID: 26378642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism.
    M Onorato A; Fiore E; Bayo J; Casali C; Fernandez-Tomé M; Rodríguez M; Domínguez L; Argemi J; Hidalgo F; Favre C; García M; Atorrasagasti C; Mazzolini GD
    Liver Int; 2021 Jul; 41(7):1677-1693. PubMed ID: 33641248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy, NAFLD and NAFLD-Related HCC.
    Wu WKK; Zhang L; Chan MTV
    Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth.
    Dashti Z; Yousefi Z; Kiani P; Taghizadeh M; Maleki MH; Borji M; Vakili O; Shafiee SM
    Metabolism; 2024 May; 154():155811. PubMed ID: 38309690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Role of Hepatic Ketogenesis in Fatty Liver Disease.
    Mooli RGR; Ramakrishnan SK
    Front Physiol; 2022; 13():946474. PubMed ID: 35860662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.